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Abstract
Background: 2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) is an enigmatic enzyme specifically expressed at
high levels in the vertebrate myelin sheath, whose function and physiological substrates are unknown. The protein
consists of two domains: an uncharacterized N-terminal domain with little homology to other proteins, and a C-
terminal phosphodiesterase domain.
Findings: In order to be able to fully characterize CNPase structurally and functionally, we have set up expression
systems for different domains of CNPase, using a total of 18 different expression constructs. CNPase was expressed
in E. coli with a TEV-cleavable His-tag. Enzymatic activity assays indicated that the purified proteins were active and
correctly folded. The folding of both the full-length protein, as well as the N- and C-terminal domains, was also
studied by synchrotron CD spectroscopy. A thermal shift assay was used to optimize buffer compositions to be
used during purification and storage. The assay also indicated that CNPase was most stable at a pH of 5.5, and
could be significantly stabilized by high salt concentrations.
Conclusions: We have been able to express and purify recombinantly several different domains of CNPase,
including the isolated N-terminal domain, which is folded mainly into a b-sheet structure. The expression system
can be used as an efficient tool to elucidate the role of CNPase in the myelin sheath.
Background
The myelin sheath is a membrane structure present in
the vertebrate nervous system, formed when a glial cell
wraps its plasma membrane several times around the
axon. Myelin facilitates the transmission of nerve
impulses, leading to up to 100 times faster impulse velo-
city in myelinated vs. non-myelinated axons. This speed
is necessary for the proper functioning of the nervous
system, and loss of myelin leads invariably to severe
complications. Myelin consists of tightly packed lipid
layers with relatively little water. This is probably a sig-
nificant factor in that the protein composition of myelin
is unique. Specific properties of myelin proteins often
include hydrophobicity and attachment to membranes
[1]. Thus, their recombinant expression and purification
are not trivial.
2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNPase)
is an enzyme expressed abundantly in myelin. In myelin,
CNPase is localized in the non-compact regions, such as
the periaxonal membrane and the paranodal regions [2].
It forms up to 4% of protein in the central nervous sys-
tem myelin and up to 0.4% in the peripheral nervous
system; thus, it is the most abundant protein in the
non-compacted myelin membrane. A post-translational
isoprenylation at a cysteine residue close to the C termi-
nus makes it possible for the protein to attach itself to
membranes [3,4]. While myelin in CNPase-deficient
mice [5] appeared normal, they develop progressive axo-
nal neurodegenerative disease. The mutants have also
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indicated roles for CNPase in axoglial interactions at the
nodes of Ranvier [6], and in proper myelination of
small-diameter axons [7]. CNPase apparently takes part
in both myelination and in a signal transduction cascade
between myelin and the axon [8]. CNPase has also been
implicated as a potential antigen and marker in autoim-
mune disease [9-11].
The enzymatic activity of CNPase, the hydrolysis of
2’,3’-cyclic nucleotides to 2’-nucleotides, was the basis of
the discovery of the enzyme from brain tissue in the
1960s [12]. The activity is specific to 2’,3’-cyclic nucleo-
tides, and the enzyme cannot hydrolyze 3’,5’-cyclic ade-
nosine monophosphate [13]. The physiological substrate
for the enzymatic reaction of CNPase has been a mys-
tery, because 2’,3’-cyclic nucleotides have not been dis-
covered in vivo. However, recently, components of RNA
metabolism have been suggested to be the in vivo sub-
strate. Mammalian CNPase was shown to be able to fill
in for the yeast tRNA ligase in tRNA repair [14], and it
was shown to bind mRNA in cultured oligodendrocytes
and inhibit translation in vitro [15].
CNPase is expressed as two isoforms, produced from
the same gene. The 20-residue extension in the N-ter-
minus of CNPase 2 functions as a mitochondrial target-
ing signal that is controlled by phosphorylation [16].
The full-length CNPase can be divided into two folded
domains. The C-terminal domain contains the phospho-
diesterase activity [13,17], and is, hence, usually termed
the catalytic domain. The crystal structure of the C-
terminal domain with residues 166-379 of human
CNPase has been determined [18]. Along with NMR
data [19], these results confirm that CNPase belongs to
the 2H phosphoesterase superfamily of proteins. This
superfamily is characterized by two His - X - Thr
motifs, forming the core of the active site. Many pro-
teins in this superfamily have functions related to RNA.
The N-terminal domain, approximately the first 180
residues, of CNPase is very poorly characterized, and its
purification has not previously been reported. It is not
necessary for the phosphodiesterase activity in vitro [17].
The N-terminal region does, however, contain an ATP
or GTP binding motif, the P-loop [20], and has a low
homology to the family of P-loop containing nucleotide
triphosphate hydrolases. Recently, binding of purine
nucleotides and weak hydrolysis of purine triphosphates
by CNPase was detected [21], but it was not experimen-
tally proven whether the binding and hydrolysis occur
in the N- or the C-terminal domain. The availability of
the purified N-terminal domain from CNPase would be
required to fully characterize such functions.
Here, we have set up an expression system for different
domains of mouse CNPase in E. coli. Constructs for both
the N- and C-terminal regions of CNPase and the full-
length protein have been prepared. Several constructs of
different length have been prepared; having multiple con-
structs for the same protein increases significantly the
chance of obtaining soluble protein and, ultimately, well-
diffracting crystals [22]. A number of the CNPase con-
structs have been used successfully for large-scale protein
expression and purification, and initial characterizations
are reported here, including assays for activity, stability,
and folding of the different domains.
Materials and methods
Vector construction
Details of the vector construction are in Additional File
1. Briefly, the Gateway system was used to subclone
inserts encoding mouse CNPase [23] into pTH27 [24].
The resulting constructs express recombinant CNPase
domains with an N-terminal His tag, removable by TEV
protease [25].
Expression and purification
For large-scale expression, plasmids were transformed
into E. coli Rosetta (DE3). A transformed colony was
picked into 10 ml LB medium with 100 μg/ml ampicillin
and 34 μg/ml chloramphenicol. The culture was grown
overnight at +37°C, and 1-10 ml of it was used to start
the large-scale culture (1000 ml) on the following day.
For the C-terminal domain of CNPase, the large-scale
culture was grown and induced at +37°C. The culture
was grown with shaking at +37°C, until the optical den-
sity at 600 nm was 0.4-0.6. Protein expression was
induced with the addition of isopropyl b-D-1-thiogalac-
topyranoside (IPTG) to 0.2 mM, and the culture was
incubated at +37°C for 3 h. The cells were collected by
centrifugation and resuspended in lysis buffer (50 mM
Na-Phosphate pH 7.5, 500 mM NaCl, 10% Glycerol and
1 mM DTT). Cells were flash-frozen in liquid nitrogen
and stored at -70°C until use.
For the large-scale expression of the N-terminal
domain of CNPase, the autoinduction medium ZYM-
5052 containing the appropriate antibiotics was used
[26]. The culture was shaken at 18°C for approximately
40 h, and the cells were collected and resuspended in
lysis buffer (50 mM Tris-HCl pH 8, 500 mM NaCl, 10%
Glycerol, 5 mM CaCl2 and 1 mM DTT). The cell sus-
pension was frozen and stored at -70°C.
The large-scale expression of the full-length protein
was initially done in a similar fashion to the C-terminal
domain, with the temperature for induction lowered to
18 - 20°C. Also, a similar autoinduction method to the
one used for the N-terminal domain was used, with the
exception that the buffer component of the lysis buffer
was HEPES at pH 7.
To lyse the cells, lysozyme was added to 0.1 mg/ml;
the cell suspension was then sonicated repeatedly, until
it appeared non-viscous. Cell debris was removed by
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centrifugation at 27000 g for 30 min. The supernatant
was applied to a Ni-TED (Macherey-Nagel) column.
The column was washed with lysis buffer until the base-
line at 280 nm was stable and elution was performed
with lysis buffer including 250 mM imidazole. TEV pro-
tease [25] was added to the sample, and the protein was
dialyzed overnight back into the lysis buffer (without
imidazole). The dialyzed protein was applied back to the
Ni-TED column, and the flow-through was collected.
The sample was concentrated to 2 ml and applied to a
Hiload 16/60 Superdex 200 or a Hiload 16/60 Superdex
75 column (GE Healthcare). The protein-containing
peaks were analyzed by SDS-PAGE, and the fractions
containing CNPase were pooled, concentrated, and
stored on ice until further use.
Thermal shift assay
The thermal shift assay was done similarly to a previous
report [27]. Measurements were made with the 7500
Real-Time PCR System, using 96-Well Optical Reaction
Plates (Applied Biosystems). Each well contained 1-5 μg
of the protein and 1-2 X SYPRO Orange dye (Molecular
Probes). The temperature was elevated steadily in 1°C
steps from 21°C to 90°C. The fluorescence of the
SYPRO Orange probe was measured using excitation at
490 nm and emission at 575 nm. Measurements were
done in duplicate or triplicate.
Enzymatic activity assays
Kinetic measurements were made as previously
described [17]. In this method, CNPase cleaves the
phosphodiester bond in 2’, 3’-cyclic NADP (cNADP)
[28]. NADP is then reduced to NADPH by glucose-6-
phosphate dehydrogenase, to transform glucose-6-phos-
phate to 6-phosphogluconolactone. The amount of
formed NADPH is directly relative to the activity of
CNPase and can be measured spectrophotometrically at
340 nm with the absorption coefficient 6.22 cm-1 mM-1.
The reaction mixture contained 100 mM MES buffer
at pH 6, 30 mM MgCl2, 5 mM glucose-6-phosphate
(Sigma) and 0,6 U glucose-6-phosphate dehydrogenase
(Sigma). The concentration of the substrate cNADP
(Sigma) was 2, 1, 0.5, 0.2, 0.1, 0.05, 0.02 and 0 mM. 500
or 5000 ng of CNPase were used. The measurements
were performed at 25°C using 96-Well UV-Star Micro-
plates (Greiner Bio-One) with the Powerwave X device
(BIO-TEK Instruments Inc.) and KC Junior software
(BIO-TEK Instruments Inc.).
Synchrotron radiation CD spectroscopy
The folding of the full-length CNPase and the N- and
C-terminal domains was studied by SRCD at the CD1
beamline of the ASTRID storage ring, ISA, Århus (Den-
mark). Prior to measurement, the proteins were dialyzed
into a buffer suitable for SRCD analysis (50 mM sodium
phosphate, 500 mM NaF, 10% glycerol, 1 mM DTT; pH
either 6 (full-length and C-terminal CNPase) or 8 (N-
terminal domain)). CD spectra were collected in the
wavelength range of 170-280 nm. The protein concen-
trations were 0.5 (full-length), 1.1 (N-terminal), and 4.7
(C-terminal) mg/ml; the pathlength was either 100 μm
(full-length and N-terminal) or 18 μm (C-terminal). The
C-terminal domain was also studied in the presence of 1
M ammonium sulfate. The spectra were processed with
CDtool [29] and analyzed using Dichroweb [30].
Results and discussion
Vector construction
A total of 18 expression clones were prepared for mouse
CNPase, as shown in Figure 1 and Additional File 2.
Eight constructs were made for the full-length protein,
six for the C-terminal domain, and four for the N-term-
inal domain. All constructs can be used to express pro-
tein that has an N-terminal hexahistidine tag, followed
by a TEV protease cleavage site and the corresponding
CNPase domain. The entry clones can also be used to
generate other expression vectors in the Gateway sys-
tem, such as those used in insect cells.
Expression & purification
Several constructs were successfully used for protein
expression. The C-terminal constructs were particularly
simple to express in large amounts; the amount of recom-
binant protein in the lysate clearly exceeds the binding
Figure 1 A schematic of the main characteristics of the CNPase
protein and of the length and relative solubility of the
prepared constructs.
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capability of the column (Figure 2A). Consequently, the
purity reached with a single purification step was good.
TEV protease cleavage did not work for the C-terminal
domain constructs prepared with forward primer 3, possi-
bly due to steric hindrance in the folded protein. Thus,
further expression of the catalytic domain was done with
constructs prepared with forward primer 6 (6 amino acid
residues longer in the N-terminus), with which the TEV
cleavage worked.
The full-length constructs had to be expressed at
lower temperatures in order to have the protein
expressed in soluble form, and less soluble protein was
obtained. The purification of the full-length protein
was done in a similar fashion to the C-terminal domain
(Figure 2B).
The expression and purification of the N-terminal
domain proved to be a much tougher task. Only one
construct (residues 20-180) out of the four that were
produced could be used to express the protein in solu-
ble form; when expressed with the autoinduction
method, and even then, only in small amounts. The
reduced expression level also makes the purification of
the N-terminal domain of CNPase more difficult.
All samples initially purified by Ni-affinity chromato-
graphy were further purified with size exclusion chroma-
tography (Figure 2C). The constructs that contain the
very C-terminal extension (residues 399-420) tend to
form stable dimers during purification. This is probably
due to the cysteine residue 417, which is part of an
unfolded tail. In fact, the observed dimers could be
Figure 2 Purification of recombinant CNPase. A. SDS-PAGE from a Ni-TED purification of a C-terminal CNPase construct. 1, soluble lysate; 2,
flow-through; 3-7, washes; 8, marker; 9-15, imidazole elutions. The calculated size for the recombinant protein was 26.7 kDa. B. SDS-PAGE from a
Ni-TED purification of a full-length CNPase construct. 1, marker; 2, soluble lysate; 3, flow-through; 4, wash; 5-7, elutions. The calculated size of the
recombinant protein was 45.2 kDa. The gels in A and B were stained with PageBlue Protein Staining Solution (Fermentas). The molecular weight
marker in both gels is the PageRuler Prestained Protein Ladder, with sizes (from bottom to top) 10, 15, 25, 35, 40, 55, 70, 100, and 130 kDa. C.
Size exclusion chromatograms (on a HiLoad 16/60 Superdex 200 column) for different CNPase constructs. The black line is a chromatogram for a
full-length CNPase (construct 2-1), the red line for the catalytic domain containing the C-terminal tail (construct 6-2), and the blue line for the
catalytic domain without the C-terminal tail (construct 6-1). The absorbance of the catalytic domain without the C-terminal tail was scaled to
10% for it to be in comparable scale. Note the dimer seen in the presence of the C-terminal tail. The elution volumes of molecular weight
markers (in kDa) are indicated above the graph.
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broken into monomers by DTT treatment (data not
shown). In vivo, this cysteine is implicated in isoprenyla-
tion [20].
The typical yield of purified protein from 1000 ml of
culture for the C-terminal constructs was tens of milli-
grams. For the full-length constructs, the yield was milli-
grams and for the N-terminal constructs much less. The
purified constructs are now being used for biochemical
characterizations and crystallization, in order to deter-
mine the structure-function relationships in CNPase.
Thermal shift assay
Initially, all buffers used in the purification were of near-
neutral pH with a low NaCl and glycerol content. The
solubility and stability of the protein did not appear to
be ideal under these conditions, as evidenced by precipi-
tation during storage. The apparent melting tempera-
tures (Tm) for full-length and C-terminal constructs
were determined under various conditions (Figure 3)
using a thermal shift assay, in the presence of SYPRO
Orange, which binds to the hydrophobic internal parts
of the unfolding protein and produces a rise in fluores-
cence upon protein denaturation. When applied in the
purification protocols, the conditions with higher Tmva-
lues were found to correlate with increased solubility
and stability of the proteins. In pH 5.5 and in the pre-
sence of 500 mM NaCl, CNPase is much more stable
than at neutral pH with lower salt content. For example,
the protein could be stored on ice at +4°C for weeks in
the optimized buffer. A rather general stabilization of
the protein was observed with different salts (Figure 3C,
D). The melting temperature and stability during purifi-
cation are both also consistently higher for the catalytic
domain than for the full-length protein. A clear correla-
tion exists between the apparent melting temperature
obtained from the assay and the behaviour of the pro-
tein during preparation and storage. See Additional file
3 for more details.
Figure 3 Graphical representation of the melting temperatures defined by the thermal shift assay. A. A selection of thermal shift assay
melting curves for the CNPase catalytic domain in pH 5.5 (0 mM NaCl, blue; 500 mM NaCl, red) and 7.5 (0 mM NaCl, green; 500 mM NaCl,
purple). A clear increase in the melting temperature can be seen from the graphs, induced by both pH 5.5 and high salt concentration. B. The
stability of the C-terminal domain in different conditions as a function of pH. Black, 150 mM NaCl; red, 500 mM NaCl; blue, 10% glycerol; green,
5% PEG400. C. The effect of different salts on the stability of the full-length protein (construct 4-1). Blue, sodium acetate; red, lithium sulfate;
black, ammonium sulfate; green, sodium phosphate; orange, sodium citrate. The buffer in the experiment was 50 mM Bis-Tris, pH 5.5. D. A
comparison between ammonium sulfate (circles) and sodium chloride (squares). See Additional File 3 for more details on the thermal shift
assays.
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Enzymatic activity measurements
The phosphodiesterase activity of CNPase was assayed
with a coupled enzyme assay [17,28]. Activity measure-
ments were made for two different full-length constructs
and two C-terminal domain constructs (Table 1). The
results clearly indicate that all tested constructs were
active in the phosphodiesterase reaction. The activity was
similar to that seen in earlier studies. Furthermore, the
C-terminal tail (22 residues) has no significant effect on
the catalytic activity; neither do the first 24 N-terminal
residues of the full-length protein.
Folding of CNPase
The folding of 3 different CNPase constructs; the full-
length protein (construct 2-1) and the isolated N- and
C-terminal domains (constructs 4-3 and 6-1) was
assessed by SRCD (Figure 4). The spectra indicate that
all 3 tested samples were folded, containing both alpha
and beta structure. The secondary structure contents
obtained using Dichroweb are listed in Table 2. Notably,
it is clear that the N-terminal domain has more b-sheet
structure and less a-helices than the C-terminal domain.
Upon comparison to the known crystal and solution
structures of the catalytic domain, the spectrum for the
C-terminal domain indicates a smaller content of helical
segments than the 3D structures.
Conclusions
CNPase is an abundant myelin protein that was discov-
ered already nearly 50 years ago [12], but whose actual
function has only recently begun to be revealed.
CNPase has been shown to bind RNA, and its physio-
logical function could be related to RNA metabolism
[14,15]. However, it is not known, how RNA is bound
by CNPase, and why it happens. We have shown here
that both the N- and C-terminal domain of recombi-
nant CNPase are folded entities, and will start thor-
ough studies on the functional properties and structure
of these domains, both in isolation and together, in the
context of full-length CNPase. Specifically, a thorough
characterization of the interactions, structure, and
function of the N-terminal domain of CNPase is
expected to shed light on the function of the enzyme
in myelin.
Additional file 1: Detailed methods for vector construction. Detailed
protocols for expression vector construction, including a table of the
used primers (Supplementary Table S1).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1756-0500-3-12-
S1.DOC ]
Additional file 2: CNPase constructs. A table describing all prepared
expression constructs, related to the information shown on Figure 1
(Supplementary Table S2).
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1756-0500-3-12-
S2.DOC ]
Additional file 3: Thermal shift assays. Detailed conditions for thermal
shift assays and additional results (Supplementary Table S3).
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The spectra were analyzed at the Dichroweb server using the CDSSTR
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